New study tracks Ribociclib's Real-World impact on early breast cancer in saudi arabia
NCT ID NCT06797531
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This study is observing about 177 people in Saudi Arabia with HR+/HER2- early breast cancer who are already taking ribociclib plus hormone therapy as part of their routine care. Researchers will track how long patients stay free from cancer returning and note any side effects. The goal is to see how well this treatment works outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGRiyadh, 11211, Saudi Arabia
-
Novartis Investigative Site
RECRUITINGRiyadh, 11426, Saudi Arabia
Conditions
Explore the condition pages connected to this study.